Designing complexity with purpose: sharing lessons from the front lines of bi- and multi-specific antibody development
02 Sept 2026
Bi/Multispecifics
- Which therapeutic area do you believe multi-specific formats will genuinely transform over the next five years, and what needs to be true scientifically or technically for that to happen?
- Where do multi-specific programs most commonly break down in your experience, target biology assumptions, CMC surprises, or clinical translation, and what does that pattern reveal about where the field still needs foundational work?
- What design strategies, (logic gating, masking, geometry engineering), have proven most valuable, and where have you had to sacrifice scientific elegance for developability?
- How do you weigh underlying biology against IP positioning and competitive strategy when choosing between a combination regimen and a single multi-specific molecule?
- Is regulatory uncertainty shaping your format decisions, and are you engaging agencies proactively?
